The cervix is the lower part of the uterus. Cancer that develops in the cervix is called cervical cancer. At present, two types of cervical cancers are notably diagnosed in women. These types include adenocarcinoma and squamous cell carcinoma. Almost all types of cervical cancer are associated with human papiloma virus (HPV). HPV 16 and HPV 18 are the most common strain of human papiloma virus associated with cervical cancer. Cervical cancer is the most widespread worldwide cancer among women population and the most regular cause of cancer-related death, accounting for almost 3,00,000 deaths annually. Early diagnosis of cervical cancer is done easily by Pap Smear Tests. Whereas, Colposcopy, HPV testing, End Cervical Curettage (ECC) are also used to diagnose cervical cancer. Cervical cancer is a sexually transmitted disease that can be easily prevented by either vaccination or early detection.
According to the report, the global cervical cancer diagnostic market accounted for USD 6.70 billion in 2015 and is expected to reach USD 9.46 billion by 2021, growing at a CAGR of around 5.9% between 2015 and 2021.
Globally, cervical cancer diagnostics test market is accelerated by increasing the prevalence of HPV infection among female population across the globe. As per, the Centers for Disease Control and Prevention, six million people in the U.S. acquire HPV infection each year. In addition, increasing the incidence of women to have multiple sex partners in developed cities considered as a major governing factor for prevailing of HPV infection which directly wires the growth cervical cancer diagnostic market. Moreover many lifestyle-related factors like smoking, obesity, unsafe sex and inherited HPV infection are considered as a secondary factor which supports in driving the cervical cancer diagnostics market. However, lack of awareness about human papiloma virus among the various class of population and unwillingness of the female population to undergo cervical cancer prognosis are considered as a major restraint for the growth of cervical cancer diagnostics market. Nonetheless, untapped market of Asia Pacific may act as major opportunities which likely to create growth avenues in nearby future.
Sample copy of report at https://www.zionmarketresearch.com/sample/cervical-cancer-diagnostic-test-market
The report provides complete forecast and analysis of the cervical cancer diagnostic market on a global and regional level. The reports summarise the historic data of 2015 along with the forecast from 2016 to 2021 based on revenue generated (USD Million). To understand the keen competitive landscape in the global market, an analysis of Porter’s Five Forces model is also done for the cervical cancer diagnostic market and has been added in the study. The report also analyzes several factors including opportunities, drivers and restraints and their impact on the global market during the forecast period. In addition, the study also encompasses a market attractiveness analysis, wherein each segment and sub-segment are used as a benchmarked which is based on their market size, growth rate, and general attractiveness.
The report covers a complete detailed segmentation of the cervical cancer diagnostic market which is based on a diagnostic test, end user & region. The regional market segment holds the largest market share in 2015.
Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. These regions are the further segmented into the U.S., UK, Germany, France, China, Japan, India, and Brazil. North America was the leading region in global cervical cancer diagnostic market in 2015 due to the huge market in the U.S. and Canada. As these countries are leading in consumption of global health care facilities. In addition, rising incidence of HPV infections and followed by growing aging population in North America region is a major driving factor for the growth of cervical cancer diagnostic market. However, European countries lie in the second position for generating revenues due to awareness among population followed by Asia Pacific. The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period due to the rising prevalence of HPV population, the government initiative, and health care infrastructure.
This report provides detailed competitive outlook including the market share and company profiles of the key participants. Key market players of cervical cancer diagnostic test market include Abbott Laboratories, Becton, Dickinson and Company, Femasys, Inc., Hologic, Inc., Guided Therapeutics, Inc., OncoHealth Corp., Quest Diagnostics, Inc., Roche Diagnostics, QIAGEN, and Zilico Ltd.